Watch for the US Food and Drug Administration to act on a trial diversity guidance, enhanced device cybersecurity, the revised quality systems regulations, and more in 2024, two industry observers said at the Regulatory Affairs Professionals Society (RAPS) Convergence meeting in Montreal.
The 4 October session was led by Alexander Gaffney, executive director of regulatory policy and intelligence at Politico’s AgencyIQ, and...